Senseonics Holdings, Inc. (SENS)
Automate Your Wheel Strategy on SENS
With Tiblio's Option Bot, you can configure your own wheel strategy including SENS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SENS
- Rev/Share 0.0329
- Book/Share 0.049
- PB 10.6207
- Debt/Equity 1.1544
- CurrentRatio 6.8845
- ROIC -0.9245
- MktCap 392231320.0
- FreeCF/Share -0.0816
- PFCF -6.6888
- PE -5.0517
- Debt/Assets 0.4659
- DivYield 0
- ROE -7.4567
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | SENS | H.C. Wainwright | -- | Buy | -- | $1.1 | June 2, 2025 |
| Initiation | SENS | Mizuho | -- | Outperform | -- | $2 | April 10, 2025 |
News
Revisiting Senseonics After 4 Years: Still A Big Investment Opportunity
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Positive
I share my recent interview with Senseonics CEO, Tim Goodnow and the CFO, Rick Sullivan. Senseonics has recently introduced a 365-day Continuous Glucose Monitoring system, aiming to disrupt a market dominated by short-term CGMs from DexCom, Abbott Laboratories, and Medtronic. The next 12 months will be crucial for Senseonics as they prove their technology and decide if they continue their commercial partnership with Ascensia, change partners to go solo.
Read More
Senseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private Placement
Published: May 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the pricing of an underwritten public offering of 100,000,000 shares of common stock at a price to the public of $0.50 per share of common stock. The gross proceeds to Senseonics from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $50,000,000. In addition, Senseonics granted the underwriters a 30-day option to purchase up to …
Read More
Sequel Med Tech and Senseonics Integrate Technologies to Create First Automated Insulin Delivery (AID) System with One-Year Continuous Glucose Monitor (CGM)
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
twiist™ expands compatibility offerings to become the first AID system compatible with Senseonics Eversense® 365 one-year CGM system
Read More
Sequel Med Tech and Senseonics Integrate Technologies to Create First Automated Insulin Delivery (AID) System with One-Year Continuous Glucose Monitor (CGM)
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
twiist™ expands compatibility offerings to become the first AID system compatible with Senseonics Eversense® 365 one-year CGM system
Read More
Senseonics (SENS) Upgraded to Buy: What Does It Mean for the Stock?
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Senseonics (SENS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
About Senseonics Holdings, Inc. (SENS)
- IPO Date 2015-12-22
- Website https://www.senseonics.com
- Industry Medical - Devices
- CEO Dr. Timothy T. Goodnow Ph.D.
- Employees 117